Table: Taisho Pharmaceutical HD - 9-MTH group results
Feb 1 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2017 Dec 31, 2016 Mar 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 215.80 216.43 279.50
(-0.3 pct) (-3.8 pct) (-0.1 pct)
Operating 28.56 26.56 33.50
(+7.5 pct) (+16.9 pct) (+4.8 pct)
Recurring 33.38 31.38 38.50
(+6.4 pct) (+7.8 pct) (+1.2 pct)
Net 26.46 23.67 30.00
(+11.8 pct) (+26.5 pct) (+4.2 pct)
EPS 331.19 yen 296.21 yen 375.47 yen
EPS Diluted 330.92 yen 296.01 yen
Ann Div 110.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10